Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × mocetinostat × Head & Neck × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 71 Cisplatin 66 Cetuximab 46 Radiotherapy 40 Nivolumab 30 Radiotherapy, Intensity-Modulated 24 Docetaxel 22 Fluorouracil 21 Paclitaxel 19 Cyclophosphamide 19 Radiation 17 Gemcitabine 17 fludarabine 16 Carboplatin 16 durvalumab 14 Erlotinib Hydrochloride 14 atezolizumab 11 Magnetic Resonance Spectroscopy 11 fludarabine phosphate 9 Radiosurgery 9 Interleukin-2 9 Drug Therapy 9 budigalimab 8 Ipilimumab 8 Bortezomib 8 Biopsy 8 130-nm albumin-bound paclitaxel 8 tremelimumab 7 Specimen Handling 7 Pemetrexed 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02993991 2017-12-29

PRIMED-001

University Health Network, Toronto

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon ⚡